ABSTRACT OBJECTIVES This study sought to assess long-term clinical outcomes in adults with nonvalvular atrial fibrillation (AF) who are ineligible for oral anticoagulation therapy and underwent left atrial appendage (LAA) ligation with the Lariat device.
A trial fibrillation (AF) is the most common arrhythmia in the world, with an estimated prevalence of 3 million in the United States (1, 2) . AF is associated with a significant, increased risk of morbidity and mortality associated with a 5-fold increase in the frequency of stroke (1) . The risk of embolic stroke in the general population increases with age, and in people over the age of 75 years, AF is among the most important causes of embolic stroke (2) .
Currently, chronic oral anticoagulation (OAC) treatment is the most frequently used prophylactic approach in patients with AF at high risk of thromboembolic events (3, 4) . However, as many as 20% of patients with AF cannot take OAC therapy (5) (6) (7) , and the risk of bleeding events while on OAC therapy can lead to increased death and disability (8) (9) (10) . Although the newer OAC medications have been shown to be either noninferior or superior to warfarin therapy with equivalent or decreased bleeding events (11) (12) (13) (14) (15) (16) , there remains a yearly 2% to 3% incidence of major bleeding (11) (12) (13) (14) (15) (16) . These OAC-contraindicated patients have limited or no options (17) (18) (19) and present a significant health care problem should a cardioembolic stroke occur (20, 21) .
The Watchman device results from PROTECT AF (Watchman Left Atrial Appendage System for Embolic
Protection in Patients with AF), the CAP (Continued Access PROTECT AF) registry, and long-term followup from Protect AF demonstrate that exclusion of the LAA is noninferior to warfarin therapy, can be implanted into the LAA with reasonable safety, and has mortality benefits when compared with warfarin therapy (22) (23) (24) . However, in the United States, the Watchman device for LAA exclusion requires OAC therapy for at least 45 days to prevent thrombus formation on the device (22) . Therefore, use of the implantable LAA exclusion devices would not mitigate the risk of bleeding in patients with contraindications to OAC therapy.
The Lariat suture delivery device (SentreHeart, Inc., Redwood City, California) is a percutaneous endocardial/epicardial approach for LAA exclusion (25, 26) . The LAA ligation approach with the Lariat suture delivery device provides a potential alternative to AF patients at high risk of thromboembolic events that have contraindications to OAC therapy. The present study assessed safety, long-term clinical efficacy of stroke prevention, and death.
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2) stroke, systemic embolism, and death of any cause.
Adverse events and clinical endpoints were selfreported and adjudicated by the principal investigator of each institution, then reviewed with a principal investigator of another institution. Two sites were new institutions with no previous experience with the Lariat procedure. Another site had performed <10 Lariat cases before enrolling its first patient. The other 2 institutions had performed >20
Lariat cases before enrolling its first patient. PERCUTANEOUS SUTURE LIGATION OF LAA. LAA ligation using the Lariat suture delivery device and accessories has been described previously (25, 26) .
Briefly, patients were prepped and draped with sterile preparation of the subxyphoid and bilateral groin regions. Once the patient was anesthetized, a TEE was performed to rule out LAA thrombus. Pericardial access using a 17-gauge Pajunk needle (Norcross, Georgia) was performed as previously described (25, 26) . Once epicardial access was obtained, serial dilation of the pericardial access was performed to allow placement of the epicardial sheath. Transseptal catheterization was performed with TEE guidance. 
Sievert et al. Sievert et al. Death rate (patient-yrs) 1.8 (7) Stroke/systemic embolism rate (patient-yrs) 1.0 (4) Death/stroke/systemic embolism rate (patient-yrs) 2.8 (11) Values are mean AE SD, n, n (%), or % (n).
LA ¼ left atrium.
Sievert et al. E n d p o i n t e v e n t s . The total patient population was followed for a total of 405.5 person-years with a mean follow-up of 2.9 AE 1.1 years. The stroke, systemic embolism, and death rates are shown in Table 2 . 
DISCUSSION
The present study supports the notion that exclusion of the LAA in patients with AF who are at risk of stroke prevents thrombus formation within the LAA with subsequent reduction of expected cardioembolic events. The event rate for stroke and systemic embolism was 1% per year, whereas the composite event rate for stroke, systemic embolism, and death of any cause was 2.8% per year. This study is consistent with previous studies with LAA occlusion devices or OAC therapy, demonstrating estimated reduction in stroke in nonvalvular AF patients (13, 15, 22, 29, 30) .
FIGURE 2 Event Rates of Strokes and Systemic Embolism and Proportion of Surviving Patients
Kaplan-Meier curves for the event rates of strokes and systemic embolism (A) and proportion of surviving patients (B).
Sievert et al. Ischemic Attack Symptoms Previously; ER ¼ event rate(s).
Sievert et al. for the final analysis. Likewise, death was prespecified as any cause, therefore discrimination between cardiovascular death and noncardiovascular death is less critical for the final analysis.
We are unable to directly assess differences in risk of stroke and embolic events against AF patients using other therapies (e.g., patients taking ASA, apixaban, LAA Ligation and Stroke Prevention
